

Info Sheet for Technical description

No. 0024

Organization

* Mandatoty fields

Name of Organization*	CynosBio, Inc.		
Address, City, States, Zip, Country*	1-3-5 Nihonbashi Horidomecho, Chuo-ku, Tokyo 103-0012, Japan		
URL	https://cynosbio.com		
Brief Descriptions of Organization* (Approx. 100 words)	CynosBio, Inc., founded in 2015, is a regenerative medicine venture developing advanced cell-based therapies in collaboration with the Foundation for Biomedical Research and Innovation at Kobe (FBRI). Its key pipeline includes TR9 (Sakracy®), an autologous oral mucosa-derived epithelial cell sheet with a human amniotic membrane substrate, which has been approved by the Ministry of Health, Labour and Welfare (MHLW), reimbursed, and already marketed in Japan, and IK-01, an autologous cartilage product currently in Phase III clinical trials for osteoarthritis. CynosBio is committed to expanding therapeutic indications and a pioneering novel cell culture technologies to deliver innovative treatments for patients with serious and intractable diseases.		
Contact address	Name*	Masahiro Matsuoka	
	Department* / Position	Manager of the President's office	
	E-mail* / TEL	info.tokyo@cynosbio.com	

What kind of technology do you want to offer? *

- ☒ **A.** Clinical Development Pipelines → Please see **Sheet [A]**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☐ Yes
- ☒ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☐ Series B
- ☐ Series C
- ☒ Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☒ Yes	
☐ No	

Filled in by*

Date*

Masahiro Matsuoka, Head of the President's Office
2025/8/18

Sheet [A] Clinical Development Pipelines**Info Sheet for Technical overview**

No. A-0024

* Mandatoty fields

Title***IK-01 (an autologous chondrocyte-based therapy designed to regenerate hyaline cartilage in the knee)****Development Phase***

- | | | |
|---|--|--|
| ☐ Basic Research | ☐ Drug Discovery | ☐ Pre-Clinical |
| ☐ Clinical Trial (Phase I) | ☐ Clinical Trial (Phase II) | ☒ Clinical Trial (Phase III) |
| ☐ Review | ☐ Others | |

Diesease Area*

- | | | |
|---|---|---|
| ☐ Cancer | ☐ Central nervous system | ☐ Ophthalmology |
| ☒ Musculoskeletal | ☐ Endocrine / Metabolism | ☐ Cardiovascular |
| ☐ Urogenital | ☐ Digestive organ | ☐ Blood |
| ☐ Infection | ☐ Dermatology | ☐ Immunity |
| ☐ Otolaryngology | ☐ Respiratory | ☐ Others |

Description*

IK-01 is an autologous chondrocyte-based therapy designed to regenerate hyaline cartilage in the knee. A Phase III clinical trial for osteoarthritis is currently underway in Japan. Unlike existing products such as JACC® in Japan and MACI® in the U.S., IK-01 is manufactured through a short, two-week cell culture process and, upon transplantation, is expected to regenerate authentic hyaline cartilage. CynosBio is seeking global partners for the development and commercialization of IK-01, with a primary focus on indications for traumatic cartilage injuries.

Filled in by***Date***

Masahiro Matsuoka, Head of the President's Office

2025/8/18